AavantiBio is a gene therapy company based in Cambridge, MA that launched with a focus on rare inherited disorders. Its lead program targets Friedreich’s Ataxia and builds on foundational research by co‑founders Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D. The company will leverage strategic partnerships with the University of Florida’s Powell Gene Therapy Center and the MDA Care Center at UF Health, where the founders maintain research and clinical practices. AavantiBio announced a $107M Series A financing at launch and previously received initial funding from patient groups. Early non‑dilutive/venture philanthropy support came from GoFAR and the Muscular Dystrophy Association Venture Philanthropy Fund. Leadership includes CEO Alexander “Bo” Cumbo, formerly of Sarepta, and a board composed of founders, investor representatives and independent directors, with Louise Rodino‑Klapac serving as a board observer.

Total raised

$107M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2020